Association between religiosity/spirituality and opioid abuse: A systematic review

2024-6-1

Mental well-being and illicit drug use related risk factors in Sri Lankan institutionalised male drug users

2024-6-1

Determination of sexual functioning, quality of life levels, and healing factors of substance-abusing men who continue the rehabilitation program in Turkey

2024-6-1

Illicit drug use among Sri Lankan school-going adolescents: A qualitative study

2024-5-1

Night eating syndrome, impulsivity, sleep disorder and craving in opioid use disorder patients in remission phase

2024-4-1

The impact of chronic pain and depression on medication for opioid use disorder treatment: A mixed-methods analysis

2024-4-1

Heroin addiction history, psychopathology and stress sensitivity in a sample of migrants to Italy

2024-4-1

Maternal buprenorphine split dosing

2024-4-1

Patterns of heroin and other illicit drug use in Sri Lanka. A detailed analysis of a country of transient point for drug trafficking

2024-4-1

The effect of intravenous heroin injection on gene expression in HIV-1 infected people

2024-4-1

Socio-demographic characteristics and patterns of Substance Use Disorder in Montenegro

2024-4-1

Liver function and lead levels increase by oral and inhaled opium use in Iranian addiction treatment centres

2024-4-1

Recruiting and retaining patients in low threshold opioid agonist treatment: A retrospective cohort study

2024-4-1

Addressing methamphetamine use in opioid use disorder treatment: Clinical perspectives

2024-4-1

HCV-RNA viral load fingerstick assay to simplify screening and linkage to care of people who use drugs attending Italian addiction treatment centres: A pilot project

2024-4-1

Group counselling can prolong the remission period in Opioid Use Disorder patients after detoxification and enhance social support, self-efficacy and hopelessness levels in patients and their families in Turkey

2024-3-1

Somatic and mental health among older patients in opioid agonist therapy: a cross-sectional geriatric assessment study

2024-3-1

International perspectives on opioid use disorder and treatment: Results from an online convenience sample

2024-3-1

Effect of changes in life-related factors on mood status and life quality of methadone maintenance therapy (MMT) patients after withdrawal from MMT

2024-3-1

Using genetic parameters to predict somatisation in females with heroin dependence

2024-3-1

Efficacy and safety of Naldemedine in the long-term treatment of opioid-induced constipation in patients on methadone agonist therapy monitored for three consecutive months

2024-3-1

The effects of heroin on pregnant rats and the reproductive system of female offspring

2024-3-1

Beginning with buprenorphine depot: characteristics and experiences of the first patients in a French addiction centre

2024-3-1

The severity of heroin use disorder in patients at treatment entry and their therapeutic response to opioid agonist treatment

2024-3-1

The relationships among withdrawal symptoms and depression in IV injection and non-injection groups in a population of heroin users

2024-3-1

The effective management of addiction: An Italian experts’ opinion using a nominal group technique (NGT) approach

2024-3-1

Psychometric evaluation of two patients monitored for 12 weeks after switching from racemic methadone to levomethadone agonist therapy

2024-3-1

Pet ownership, physical activity and mental health among people in opioid maintenance treatment: A prospective, observational study

2024-3-1

Satisfaction of patients on methadone maintenance treatment with changing policies during the COVID-19 pandemic

2024-3-1

Is the SCL90-based five-dimensional structure able to differentiate heroin use disorder patients with low and high benzodiazepine dependence symptomatology?

2024-3-1

Invisible: An exploratory study of the impact of COVID-19 restrictions on people who use heroin

2024-3-1

Suicidal behaviour and its risk factors in patients with Opioid Use Disorder

2024-3-1

“Life feels better with the right medication”. Results from a service user organization-led survey of opioid maintenance treatment patients in Norway

2024-3-1

Micro-dosing with buprenorphine when switching from full agonists (methadone, SR-morphine) to buprenorphine treatment in opioid agonist-assisted treatment programmes in Slovenia

2024-3-1

A community-based telemedication-assisted treatment (TMAT) for delivery of methadone maintenance treatment (MMT) during the COVID-19 pandemic in India: A single-arm, prospective feasibility study

2024-3-1

Traditional Chinese medicine-based medication-assisted therapy for switching from methadone to buprenorphine/naloxone in treating opioid use disorder

2021-8-1

Caring for opioid drug users during the COVID-19 pandemic - a commentary on the Irish experience

2021-6-1

Risk of sleep disordered breathing and treatment dilemma while on methadone maintenance treatment in opioid use disorder patients

2021-2-1

Real-world retention rates with a long-acting buprenorphine depot in opioid-dependent patients attending private clinics in Australia

2021-1-1

Outcomes for patients receiving telemedicine-delivered medication-based treatment for Opioid Use Disorder: A retrospective chart review.

2021-1-1

Methadone as a treatment option for restless leg syndrome in opioid use disorder patient

2020-10-1

Childrens psychological well-being, anxiety, depression, and stress: The role of addicted and non-addicted parents

2020-6-12

Mood stabilizing effects of methadone in opioid use disorder patient

2020-2-1

Cross-sectional study on the need to provide contraceptive services to women attending opioid-substitution therapy

2019-8-1

Additional comments to Staub et al., “How to develop and implement an exercise programme in a heroin-assisted treatment setting”

2019-5-4

Self-reported adverse experiences and age of opioid onset for first time admitted to opioid maintenance treatment

2019-1-1

‘You should be helping him, he’s trying to do something about it’: The dilemma of heroin use, agonist opioid treatment and employment

2018-12-1

Methadone dose as a determinant of infant outcome during the peri and postnatal period

2018-4-1

Switching between lyophilized and sub-lingual Buprenorphine formulations in Opioid-Dependent Patients: Observations on medication transfer during a Safety and Pharmacokinetic Study

2018-3-2

An evaluation of community pharmacist perception of the misuse and abuse of over-the-counter co-codamol in Cornwall and Devon, UK: a cross-sectional survey

2018-2-21